TARSUS PHARMACEUTICALS INC (TARS) Stock Price, Quote, News and Overview
NASDAQ:TARS - Nasdaq - US87650L1035 - Common Stock - Currency: USD
TARS Quote, Performance and Key Statistics
41.29
-4.25 (-9.33%)
The current stock price of TARS is 41.29 USD. In the past month the price decreased by -19.75%. In the past year, price increased by 11.75%.
TARS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 69.37 | 856.10B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 28.25 | 403.73B | ||
| JNJ | JOHNSON & JOHNSON | 16.63 | 399.88B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.89 | 233.83B | ||
| MRK | MERCK & CO. INC. | 11.97 | 231.28B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.81 | 216.51B | ||
| PFE | PFIZER INC | 8.6 | 151.54B | ||
| SNY | SANOFI-ADR | 13.65 | 137.62B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 51.06 | 118.06B | ||
| GSK | GSK PLC-SPON ADR | 8.14 | 78.28B | ||
| ZTS | ZOETIS INC | 28.47 | 76.04B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.64 | 45.53B |
Related stock screener links
About TARS
Company Profile
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. The company is headquartered in Irvine, California and currently employs 244 full-time employees. The company went IPO on 2020-10-16. The firm is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The firm investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-03 for the potential treatment of Meibomian Gland Disease (MGD), TP-04, a novel gel formulation of lotilaner for the potential treatment of rosacea, and TP-05, a novel investigative oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
Company Info
TARSUS PHARMACEUTICALS INC
15440 Laguna Canyon Road
Irvine CALIFORNIA 92618 US
CEO: Bobak Azamian
Employees: 244
Company Website: https://www.tarsusrx.com/
Investor Relations: https://ir.tarsusrx.com/
Phone: 19494099820
TARSUS PHARMACEUTICALS INC / TARS FAQ
What is the stock price of TARSUS PHARMACEUTICALS INC today?
The current stock price of TARS is 41.29 USD. The price decreased by -9.33% in the last trading session.
What is the ticker symbol for TARSUS PHARMACEUTICALS INC stock?
The exchange symbol of TARSUS PHARMACEUTICALS INC is TARS and it is listed on the Nasdaq exchange.
On which exchange is TARS stock listed?
TARS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TARSUS PHARMACEUTICALS INC stock?
15 analysts have analysed TARS and the average price target is 68.72 USD. This implies a price increase of 66.44% is expected in the next year compared to the current price of 41.29. Check the TARSUS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TARSUS PHARMACEUTICALS INC worth?
TARSUS PHARMACEUTICALS INC (TARS) has a market capitalization of 1.58B USD. This makes TARS a Small Cap stock.
How many employees does TARSUS PHARMACEUTICALS INC have?
TARSUS PHARMACEUTICALS INC (TARS) currently has 244 employees.
What are the support and resistance levels for TARSUS PHARMACEUTICALS INC (TARS) stock?
TARSUS PHARMACEUTICALS INC (TARS) has a support level at 28.15 and a resistance level at 56.2. Check the full technical report for a detailed analysis of TARS support and resistance levels.
Is TARSUS PHARMACEUTICALS INC (TARS) expected to grow?
The Revenue of TARSUS PHARMACEUTICALS INC (TARS) is expected to grow by 1671.91% in the next year. Check the estimates tab for more information on the TARS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TARSUS PHARMACEUTICALS INC (TARS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TARS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TARS, evaluating the profitability, health, valuation and growth aspects
- TARSUS PHARMACEUTICALS INC (TARS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TARSUS PHARMACEUTICALS INC (TARS) Sales and EPS estimates to see what analysts future expectations are.
- TARSUS PHARMACEUTICALS INC (TARS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TARSUS PHARMACEUTICALS INC (TARS) Insider and Institutional Ownership to learn about the owners and their transactions.
- TARSUS PHARMACEUTICALS INC (TARS) Stock Chart to make your own analysis
- TARSUS PHARMACEUTICALS INC (TARS) Latest news and press-releases to stay up to date.
Does TARSUS PHARMACEUTICALS INC (TARS) stock pay dividends?
TARS does not pay a dividend.
When does TARSUS PHARMACEUTICALS INC (TARS) report earnings?
TARSUS PHARMACEUTICALS INC (TARS) will report earnings on 2025-03-17, after the market close.
What is the Price/Earnings (PE) ratio of TARSUS PHARMACEUTICALS INC (TARS)?
TARSUS PHARMACEUTICALS INC (TARS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.1).
What is the Short Interest ratio of TARSUS PHARMACEUTICALS INC (TARS) stock?
The outstanding short interest for TARSUS PHARMACEUTICALS INC (TARS) is 23.11% of its float. Check the ownership tab for more information on the TARS short interest.
TARS Technical Analysis
TARS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TARS. TARS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TARS Financial Highlights
Over the last trailing twelve months TARS reported a non-GAAP Earnings per Share(EPS) of -3.1. The EPS increased by 33.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.7% | ||
| ROE | -56.57% | ||
| Debt/Equity | 0.3 |
TARS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to TARS. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 29.25% and a revenue growth 1671.91% for TARS